- In November 2024, Clariant introduced eight new high-performing pharmaceutical excipients at the CPHI India 2024 trade show. These excipients are designed to support the development of safe and effective medicines, catering to applications such as sensitive APIs, parenteral formulations, and formulations requiring colorless solutions
- In January 2025, Roquette launched three new excipient grades specifically designed for moisture-sensitive active pharmaceutical ingredients (APIs), enhancing stability and efficacy in challenging formulations
- In January 2025, Evonik expanded its portfolio of lipid-based pharmaceutical excipients through strategic acquisitions, supporting the growing demand for novel drug delivery systems and high-quality excipients that improve bioavailability and stability
- In January 2025, Akums Drugs and Pharmaceuticals announced the development of a new facility dedicated to lyophilized and sterile dosage manufacturing, focusing on injectables and biologics, to meet the increasing demand for sterile and biologic drugs
- In September 2024, Glenmark Pharmaceuticals launched a biosimilar variant of the anti-diabetic drug Liraglutide, marking a pioneering endeavor in the Indian pharmaceutical landscape and expanding its biologics portfolio
